Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy

Abstract

Abstract Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.

Keywords

• bruton tyrosine kinase inhibitors
• chronic lymphocytic leukemia
• ibrutinib
• multiple myeloma